Daliresp
Product intended to target chronic obstructive pulmonary disease and formulated to alleviate respiratory inflammation.
Strengths: 500mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Daxas
- Therapeutic class
Phosphodiesterase-4 Inhibitor
- Pharmacological class
PDE4 Inhibitor
- Minor side effects
diarrhoea; nausea; weight loss; abdominal pain
- Moderate side effects
headache; insomnia; anxiety
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
AstraZeneca
- Onset Time
2–4 weeks
- Duration
24 hours
- Storage instructions
Store at room temperature in a dry place.
- Drug interactions
rifampicin; phenobarbital; carbamazepine; phenytoin
- Age restrictions
Not for use in those under 18 years.
- Pregnancy and breastfeeding
Pregnancy: Avoid. Breastfeeding: Avoid.
Contraindications
hypersensitivity; moderate to severe hepatic impairment; severe immunological diseases; severe acute infectious diseases
Precautions and warnings
monitor weight regularly; use with caution in history of depression; discontinue if suicidal ideation occurs
Serious side effects
suicidal ideation — requires immediate medical attention; severe depression — requires immediate medical attention; anaphylaxis — requires immediate medical attention
Patient summary
Product intended to target chronic obstructive pulmonary disease and formulated to alleviate respiratory inflammation.
Mechanism of action
This medicine inhibits phosphodiesterase-4, an enzyme involved in inflammatory processes, reducing inflammation in the airways to improve breathing in chronic respiratory conditions.
Daliresp
Product intended to target chronic obstructive pulmonary disease and formulated to alleviate respiratory inflammation.
Editorial Notes
- Active ingredient(s): Roflumilast
- Listed indication(s): Chronic Obstructive Pulmonary Disease
Available option
- 90 tablets - 500 mg1064-500-mg-14813